We are live on
!
Find out more
BLC
Brown, Lisle/Cummings Portfolio holdings
AUM
$400M
1-Year Est. Return
18.79%
This Fund
S&P 500
This Quarter
Est. Return
+5.82%
1 Year Est. Return
+18.79%
3 Year Est. Return
+61.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$224M
AUM Growth
+$26.5M
(+13%)
Cap. Flow
+$16.5M
Cap. Flow
% of AUM
7.39%
Top 10 Holdings %
Top 10 Hldgs %
27.71%
Holding
558
New
25
Increased
144
Reduced
58
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Canadian National Railway
CNI
|
+$1.38M |
| 2 |
JPMorgan Chase
JPM
|
+$932K |
| 3 |
T. Rowe Price
TROW
|
+$814K |
| 4 |
Johnson & Johnson
JNJ
|
+$659K |
| 5 |
SCHW
Charles Schwab
SCHW
|
+$636K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$256K |
| 2 |
AB InBev
BUD
|
+$191K |
| 3 |
GE Aerospace
GE
|
+$138K |
| 4 |
Gilead Sciences
GILD
|
+$108K |
| 5 |
Intel
INTC
|
+$72.9K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.74% |
| 2 | Technology | 16.33% |
| 3 | Financials | 12.83% |
| 4 | Industrials | 8.85% |
| 5 | Communication Services | 6.48% |
Similar funds
JGCM
AIM
SFCL
TGV
DBIA
MAG
BWA
KHCM
Brown, Lisle/Cummings's Q2 2023 Portfolio in Review
As of Q2 2023, Brown, Lisle/Cummings held 558 positions worth $224M, up 13% from $197M the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Brown, Lisle/Cummings deployed $16.5M of net new capital in Q2 2023, opening 25 new positions and adding to 144 existing holdings. Its largest new stake was Charles Schwab: 12,150 shares worth $689K.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, down from 19% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $256K trimmed.
- Brown, Lisle/Cummings's largest Q2 2023 buy was Charles Schwab: 12,150 shares worth $689K.
- Brown, Lisle/Cummings added most to Canadian National Railway in Q2 2023, an estimated $1.38M increase.
- Brown, Lisle/Cummings's biggest Q2 2023 reduction was Bristol-Myers Squibb, cutting an estimated $256K.
- Brown, Lisle/Cummings fully exited J.M. Smucker in Q2 2023, selling an estimated $15.7K.
- Brown, Lisle/Cummings's ten largest holdings make up 28% of its $224M portfolio in Q2 2023.
- Brown, Lisle/Cummings opened 25 new positions and closed 2 in Q2 2023.
- Brown, Lisle/Cummings's portfolio value rose 13% quarter-over-quarter to $224M.
Based on Brown, Lisle/Cummings's 13F filing for Q2 2023, filed 1 Jul 2024.